title: Indirect immunotargeting of cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system.
abstract: Cis-diamminedichloroplatinum (II) (cis-Pt) complexed to a carboxymethyl dextran-avidin conjugate was targeted to biotin-monoclonal antibody 108 (b-MAb 108). This MAb recognizes the extracellular domain of the epidermal growth factor receptor (EGF-R) on human epidermoid carcinoma (KB) cells over-expressing EGF-R. Cis-Pt-carboxymethyl-dextran-avidin (Pt-dex-Av) containing 60-90 M cis-Pt/M avidin was administered 24 hr following b-MAb108 containing 3-5 M biotin/M MAb. This treatment was potentially more effective in suppressing the growth of established KB tumor xenografts, or in inhibiting the development of lung metastases in nude mice, than free MAb 108, free drug or MAb 108 followed by drug. Replacing b-MAb 108 by unbiotinylated antibody or by b-MAb of a different specificity also yielded lower suppressive effects. The sequential administration of Pt-dex-Av following b-MAb was more effective than introduction of the Pt-dex-Av when already complexed to b-MAb 108. The results presented in this preliminary investigation suggest that Pt-dex-Av is specifically removed from the circulation by b-MAb 108 concentrated at the tumor site.
authors.affiliation: Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Schechter
authors.forename: R
authors.initials: R
authors.lastname: Arnon
authors.forename: M
authors.initials: M
authors.lastname: Wilchek
authors.forename: J
authors.initials: J
authors.lastname: Schlessinger
authors.forename: E
authors.initials: E
authors.lastname: Hurwitz
authors.forename: E
authors.initials: E
authors.lastname: Aboud-Pirak
authors.forename: M
authors.initials: M
authors.lastname: Sela
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D001360:Avidin; D001710:Biotin; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003911:Dextrans; D004334:Drug Administration Schedule; D004337:Drug Carriers; D006801:Humans; D007624:KB Cells / Q000187:drug effects*; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D003911:Dextrans; D004337:Drug Carriers; D001360:Avidin; D001710:Biotin; C014392:carboxymethyl dextran; D002945:Cisplatin